Skip to main content
. 2021 Jan 21;13:9. doi: 10.1186/s13098-021-00628-5

Table 2.

Baseline treatment of patients

Treatment at admission Third month treatment
Metformin, n (%) 42 (100) 42 (100)
DPP-4 inhibitors, n (%) 22 (52.4) 28 (66)
Sulphonylurea, n (%) 10 (23.8) 7 (16.6)
SGLT- 2 inhibitors, n (%) 9 (21.4) 21 (50)
Glinide, n (%) 2 (4.8) 1 (2.3)
Basal insulin, n (%) 36 (85.7) 40 (95)
Regular Insulin, n (%) 22 (52.4) 31 (73.8)

DPP-4 dipeptidyl peptidase-4, SGLT Sodium-glucose co-transporter-2, Glinide (meglitinide)